173 related articles for article (PubMed ID: 38268317)
1. Regional and bilateral MRI and gene signatures in facioscapulohumeral dystrophy: implications for clinical trial design and mechanisms of disease progression.
Wong CJ; Friedman SD; Snider L; Bennett SR; Jones TI; Jones PL; Shaw DWW; Blemker SS; Riem L; DuCharme O; Lemmers RJFL; van der Maarel SM; Wang LH; Tawil R; Statland JM; Tapscott SJ
Hum Mol Genet; 2024 Apr; 33(8):698-708. PubMed ID: 38268317
[TBL] [Abstract][Full Text] [Related]
2. Validation of the association between MRI and gene signatures in facioscapulohumeral dystrophy muscle: implications for clinical trial design.
Wong CJ; Friedman SD; Snider L; Bennett SR; Jones TI; Jones PL; Shaw DWW; Blemker SS; Riem L; DuCharme O; Lemmers RJFL; van der Maarel SRM; Wang LH; Tawil R; Statland JM; Tapscott SJ
bioRxiv; 2023 Feb; ():. PubMed ID: 36865168
[TBL] [Abstract][Full Text] [Related]
3. Facioscapulohumeral dystrophy transcriptome signatures correlate with different stages of disease and are marked by different MRI biomarkers.
van den Heuvel A; Lassche S; Mul K; Greco A; San León Granado D; Heerschap A; Küsters B; Tapscott SJ; Voermans NC; van Engelen BGM; van der Maarel SM
Sci Rep; 2022 Jan; 12(1):1426. PubMed ID: 35082321
[TBL] [Abstract][Full Text] [Related]
4. MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD.
Wang LH; Friedman SD; Shaw D; Snider L; Wong CJ; Budech CB; Poliachik SL; Gove NE; Lewis LM; Campbell AE; Lemmers RJFL; Maarel SM; Tapscott SJ; Tawil RN
Hum Mol Genet; 2019 Feb; 28(3):476-486. PubMed ID: 30312408
[TBL] [Abstract][Full Text] [Related]
5. DUX4 expressing immortalized FSHD lymphoblastoid cells express genes elevated in FSHD muscle biopsies, correlating with the early stages of inflammation.
Banerji CRS; Panamarova M; Zammit PS
Hum Mol Genet; 2020 Aug; 29(14):2285-2299. PubMed ID: 32242220
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal measures of RNA expression and disease activity in FSHD muscle biopsies.
Wong CJ; Wang LH; Friedman SD; Shaw D; Campbell AE; Budech CB; Lewis LM; Lemmers RJFL; Statland JM; van der Maarel SM; Tawil RN; Tapscott SJ
Hum Mol Genet; 2020 Apr; 29(6):1030-1043. PubMed ID: 32083293
[TBL] [Abstract][Full Text] [Related]
7. PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level.
Banerji CRS; Zammit PS
Hum Mol Genet; 2019 Jul; 28(13):2224-2236. PubMed ID: 31067297
[TBL] [Abstract][Full Text] [Related]
8. Influence of
Duranti E; Villa C
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298453
[TBL] [Abstract][Full Text] [Related]
9. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis.
Jones TI; Chen JC; Rahimov F; Homma S; Arashiro P; Beermann ML; King OD; Miller JB; Kunkel LM; Emerson CP; Wagner KR; Jones PL
Hum Mol Genet; 2012 Oct; 21(20):4419-30. PubMed ID: 22798623
[TBL] [Abstract][Full Text] [Related]
10. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
Jones TI; Chew GL; Barraza-Flores P; Schreier S; Ramirez M; Wuebbles RD; Burkin DJ; Bradley RK; Jones PL
Skelet Muscle; 2020 Apr; 10(1):8. PubMed ID: 32278354
[TBL] [Abstract][Full Text] [Related]
11. PAX7 target gene repression associates with FSHD progression and pathology over 1 year.
Banerji CRS
Hum Mol Genet; 2020 Aug; 29(13):2124-2133. PubMed ID: 32347924
[TBL] [Abstract][Full Text] [Related]
12. DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle.
Yao Z; Snider L; Balog J; Lemmers RJ; Van Der Maarel SM; Tawil R; Tapscott SJ
Hum Mol Genet; 2014 Oct; 23(20):5342-52. PubMed ID: 24861551
[TBL] [Abstract][Full Text] [Related]
13. The prospects of targeting DUX4 in facioscapulohumeral muscular dystrophy.
Bouwman LF; van der Maarel SM; de Greef JC
Curr Opin Neurol; 2020 Oct; 33(5):635-640. PubMed ID: 32796277
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase A activation inhibits
Cruz JM; Hupper N; Wilson LS; Concannon JB; Wang Y; Oberhauser B; Patora-Komisarska K; Zhang Y; Glass DJ; Trendelenburg AU; Clarke BA
J Biol Chem; 2018 Jul; 293(30):11837-11849. PubMed ID: 29899111
[TBL] [Abstract][Full Text] [Related]
15. DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy.
Geng LN; Yao Z; Snider L; Fong AP; Cech JN; Young JM; van der Maarel SM; Ruzzo WL; Gentleman RC; Tawil R; Tapscott SJ
Dev Cell; 2012 Jan; 22(1):38-51. PubMed ID: 22209328
[TBL] [Abstract][Full Text] [Related]
16. Muscle eosinophilia is a hallmark of chronic disease in facioscapulohumeral muscular dystrophy.
Nunes AM; Ramirez MM; Garcia-Collazo E; Jones TI; Jones PL
Hum Mol Genet; 2024 May; 33(10):872-883. PubMed ID: 38340007
[TBL] [Abstract][Full Text] [Related]
17. Muscle xenografts reproduce key molecular features of facioscapulohumeral muscular dystrophy.
Mueller AL; O'Neill A; Jones TI; Llach A; Rojas LA; Sakellariou P; Stadler G; Wright WE; Eyerman D; Jones PL; Bloch RJ
Exp Neurol; 2019 Oct; 320():113011. PubMed ID: 31306642
[TBL] [Abstract][Full Text] [Related]
18. Identification of candidate miRNA biomarkers for facioscapulohumeral muscular dystrophy using DUX4-based mouse models.
Nunes AM; Ramirez M; Jones TI; Jones PL
Dis Model Mech; 2021 Aug; 14(8):. PubMed ID: 34338285
[TBL] [Abstract][Full Text] [Related]
19. Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7.
Banerji CRS; Zammit PS
EMBO Mol Med; 2021 Aug; 13(8):e13695. PubMed ID: 34151531
[TBL] [Abstract][Full Text] [Related]
20. Single-cell RNA sequencing in facioscapulohumeral muscular dystrophy disease etiology and development.
van den Heuvel A; Mahfouz A; Kloet SL; Balog J; van Engelen BGM; Tawil R; Tapscott SJ; van der Maarel SM
Hum Mol Genet; 2019 Apr; 28(7):1064-1075. PubMed ID: 30445587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]